Reinout Hesselink

Reinout Hesselink, PhD, is the owner of R.H. Cell Therapy Consulting, providing senior-level consultancy in the ATMP field. Reinout has experience in strategy, quality, process development, CMC/ Regulatory of cell and gene therapies, and translation towards commercial production. Reinout also currently serves as the Chief Technology Officer at Stimuliver, VP process development and CMC at Pan Cancer T, ATMP process architect at Antleron, and has previous roles in quality management, process development, and business development in the cell and gene therapy industry. Reinout holds a PhD in Skeletal muscle damage and regeneration from Maastricht University.